Repaglinide is an anti-diabetic agent belongs to the meglitinide class of short-acting insulin secretagogues.
Repaglinide is indicated for the treatment of non-insulin-dependent diabetes mellitus (type 2 diabetes).
It is formulated as tablets for oral route of administration.
Mechanism of action:
Repaglinide closes ATP-dependent potassium channels in the beta-cell membrane by binding at characterizable sites. It acts an ATP Binding Cassette Sub Family C Member 8 inhibitor. This potassium channel blockade depolarizes the beta-cell, which leads to an opening of calcium channels. The resulting increased calcium influx induces insulin secretion.